Inventor · disambiguated record
Catherine R. O'Riordan
Also filed as: O'RIORDAN CATHERINE · O'RIORDAN CATHERINE R · ORIORDAN CATHERINE
23 granted patents·11 pending applications·200 citations·filing 1997–2025
95Inventor score
Top patents by PatentIndex Score
34 records- 0193US9034836B2Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersDODGE JAMES·Filed 2008·Granted May 19, 2015·27 cites·9 claims
- 0291US10821154B2Compositions and methods for treating spinal muscular atrophyGENZYME CORP·Filed 2013·Granted Nov 3, 2020·7 cites·19 claims
- 0391US10429288B2Analytical ultracentrifugation for characterization of recombinant viral particlesGENZYME CORP·Filed 2016·Granted Oct 1, 2019·5 cites·34 claims
- 0491US6287857B1Nucleic acid delivery vehiclesGENZYME CORP·Filed 1999·Granted Sep 11, 2001·115 cites·2 claims
- 0590US11639887B2Analytical ultracentrifugation for characterization of recombinant viral particlesGENZYME CORP·Filed 2019·Granted May 2, 2023·3 cites·22 claims
- 0688US10920245B2Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersGENZYME CORP·Filed 2017·Granted Feb 16, 2021·3 cites·3 claims
- 0787US12031894B2Analytical ultracentrifugation for characterization of recombinant viral particlesGENZYME CORP·Filed 2023·Granted Jul 9, 2024·0 cites·30 claims
- 0887US12013326B2Analytical ultracentrifugation for characterization of recombinant viral particlesGENZYME CORP·Filed 2023·Granted Jun 18, 2024·0 cites·30 claims
- 0987US2024393222A1Analytical ultracentrifugation for characterization of recombinant viral particlesGENZYME CORP·Filed 2024·Application pending·0 cites
- 1085US10744210B2Gene therapy for spinal cord disordersDODGE JAMES·Filed 2007·Granted Aug 18, 2020·8 cites·10 claims
- 1184US12085494B2Analytical ultracentrifugation for characterization of recombinant viral particlesGENZYME CORP·Filed 2023·Granted Sep 10, 2024·0 cites·21 claims
- 1284US11103598B2Gene therapy for retinitis pigmentosaGENZYME CORP·Filed 2019·Granted Aug 31, 2021·2 cites·28 claims
- 1380US12331296B2Variant RNAiGENZYME CORP·Filed 2023·Granted Jun 17, 2025·0 cites·23 claims
- 1480US11603529B2Variant RNAiGENZYME CORP·Filed 2018·Granted Mar 14, 2023·1 cites·43 claims
- 1580US10760079B2Variant RNAiGENZYME CORP·Filed 2019·Granted Sep 1, 2020·1 cites·41 claims
- 1680US2024182896A1VARIANT RNAiGENZYME CORP·Filed 2023·Application pending·0 cites
- 1777US10383953B2Gene therapy for retinitis pigmentosaGENZYME CORP·Filed 2015·Granted Aug 20, 2019·3 cites·45 claims
- 1877US9890394B2Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersORIORDAN CATHERINE·Filed 2009·Granted Feb 13, 2018·4 cites·11 claims
- 1977US2024000886A1Compositions and Methods for Treating Spinal Muscular AtrophyGENZYME CORP·Filed 2023·Application pending·0 cites
- 2076US2025290075A1VARIANT RNAiGENZYME CORP·Filed 2025·Application pending·0 cites
- 2175US11554161B2Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersGENZYME CORP·Filed 2019·Granted Jan 17, 2023·0 cites·4 claims
- 2275US10035829B2Methods to produce rod-derived cone viability factor (RDCVF)GENZYME CORP·Filed 2017·Granted Jul 31, 2018·1 cites·15 claims
- 2371US12201698B2Gene therapy for retinitis pigmentosaGENZYME CORP·Filed 2021·Granted Jan 21, 2025·0 cites·16 claims
- 2470US10450563B2Variant RNAiGENZYME CORP·Filed 2016·Granted Oct 22, 2019·1 cites·33 claims
- 2568US9567382B2Methods to produce rod-derived cone viability factor (RdCVF)O'RIORDAN CATHERINE R·Filed 2009·Granted Feb 14, 2017·1 cites·16 claims
- 2666US2021121523A1Compositions and methods for treating spinal muscular atrophyGENZYME CORP·Filed 2020·Application pending·0 cites
- 2765US2024384271A1Targeted gene therapy for dm-1 myotonic dystrophyGENZYME CORP·Filed 2024·Application pending·0 cites
- 2862US2021008227A1Gene therapy for spinal cord disordersGENZYME CORP·Filed 2020·Application pending·0 cites
- 2961US2023365968A1Targeted gene therapy for dm-1 myotonic dystrophyGENZYME CORP·Filed 2023·Application pending·0 cites
- 3059US2019055293A1Methods to produce rod-derived cone viability factor (rdcvf)GENZYME CORP·Filed 2018·Application pending·0 cites
- 3154US5939536AMethods for purifying cystic fibrosis transmembrane conductance regulationGENZYME CORP·Filed 1997·Granted Aug 17, 1999·12 cites·4 claims
- 3250US2016067312A1Gene therapy for amyotrophic lateral sclerosis and other spinal cord disordersGENZYME CORP·Filed 2015·Application pending·0 cites
- 3347US2003180261A1Polymer-modified virusesFiled 2003·Application pending·0 cites
- 3437US6569426B2Tresyl-monomethoxypolyethylene glycol-modified viruses having viral infectivityGENZYME CORP·Filed 1999·Granted May 27, 2003·6 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when Catherine R. O'Riordan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →